Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $305.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 42.07% to $305.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $935.2 million through Dec 2025, up 8.83% year-over-year, with the annual reading at $305.9 million for FY2025, 42.07% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $305.9 million at LENZ Therapeutics, up from $210.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $378.6 million in Q1 2022, with the low at $201.3 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 4 years is $269.8 million, with a median of $266.2 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 29.9% in 2024, then surged 42.07% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $321.9 million in 2022, then decreased by 17.3% to $266.2 million in 2023, then fell by 19.13% to $215.3 million in 2024, then skyrocketed by 42.07% to $305.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $305.9 million, $210.7 million, and $217.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.